| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-03-23 | Immunogen (USA - MA) Takeda Pharmaceutical (Japan) | antibody-drug conjugate (ADC) technology | licensing
|
Cancer - Oncology | Licensing agreement | |
| 2015-03-20 | Sanofi (France) Evotec (Germany) | collaboration |
Cancer - Oncology - Technology - Services | Collaboration agreement | ||
| 2015-03-20 | GSK (UK) Molmed (Italy) | gene therapies based on viral vector cellular transduction | collaboration development manufacturing production |
Rare diseases - Genetic diseases | Development agreement | |
| 2015-03-19 | AstraZeneca (UK) Daiichi Sankyo (Japan) | Movantik™ (naloxegol) | opioid-induced constipation (OIC) for adult patients 18 years and older | commercialisation |
Digestive diseases - Cancer -Oncology | Commercialisation agreement |
| 2015-03-19 | AbbVie (USA - IL) C2N Diagnostics (USA - MO) | anti-tau antibodies | Alzheimer\'s disease and other neurological disorders | licensing |
Neurodegenerative diseases - Neurological diseases | Licensing agreement |
| 2015-03-19 | Eli Lilly (USA - IN) Hanmi Pharmaceutical (South Korea) | HM71224 | licensing collaboration |
Autoimmune diseases | Licensing agreement | |
| 2015-03-19 | Pharming (The Netherlands) | nomination |
Rare diseases | Nomination | ||
| 2015-03-19 | PTC Therapeutics (USA - NJ) University of Pennsylvania (USA - PA) | new treatments for orphan disorders including Translarna™ (ataluren) | orphan diseases including mucopolysaccharidosis I | R&D collaboration |
Rare diseases | R&D agreement |
| 2015-03-19 | Xencor (USA - CA) | nomination |
Allergic diseases - Autoimmune diseases - Respiratory diseases - Cancer - Oncology | Nomination | ||
| 2015-03-19 | Roche (Switzerland) Sigma-Aldrich (USA - MO) | biochemical reagents product portfolio | distribution |
Diagnostic - Technology - Services | Distribution agreement | |
| 2015-03-19 | Intarcia Therapeutics (USA - CA) Numab (Switzerland) | multi-specific antibodies addressing diabetes, obesity and autoimmune indications | diabetes, obesity and autoimmune diseases | collaboration |
Autoimmune diseases - Metabolic diseases | Collaboration agreement |
| 2015-03-18 | Nanobiotix (France) CordenPharma (Germany) | NBTXR3 | services contract |
Cancer - Oncology | Services contract | |
| 2015-03-18 | Cortendo (Sweden) | nomination |
Rare diseases - Hormonal diseases - Endocrine diseases | Nomination | ||
| 2015-03-17 | Quantum Genomics (France) Inserm (France) | hypertension | creation of a joint laboratory |
Cardiovascular diseases | Opening of new premises | |
| 2015-03-17 | Teva Pharmaceutical Industries (Israel) Ignyta (USA - CA) | CEP-32496 (RXDX-105), CEP-40783 (RXDX-106), CEP-40125 (RXDX-107),TEV-44229 (RXDX-108) | product acquisition |
Cancer - Oncology | Product acquisition | |
| 2015-03-17 | Molecular Partners (Switzerland) | nomination |
Nomination | |||
| 2015-03-17 | Broad Institute of MIT and Harvard (USA - MA) Calico (USA - CA) | age-related diseases | R&D collaboration |
Collaboration agreement | ||
| 2015-03-17 | Actavis (Ireland) | nomination |
Nomination | |||
| 2015-03-17 | Polyphor (Switzerland) | nomination |
Nomination | |||
| 2015-03-17 | Valneva (France- Austria) Jianshun Biosciences (China) | EB66® cell line | human and veterinary vaccines | licensing |
Infectious diseases - Veterinary medicine | Licensing agreement |
